By: buckaroobanzai10
27 Jan 2004, 02:50 PM EST
Msg. 136585 of 136607
(This msg. is a reply to 136546 by FoxChase1803.)
Jump to msg. #  

Dr. D'Olimpio has no laboratory research group of his own at North Shore Hospital or NYU or elsewhere. A review of his publications on PubMed shows that his research has mainly been clinical research on cancer patients. I am pretty sure that the in vitro laboratory research data that forms this abstract was initiated and done by the Yonkers scientists, and that Dr. D'Olimpio is merely presenting their work as company "Spokesperson-at-large". Of course, it doesn't hurt Jimbo's academic standing and reputation to jump on the scientific bandwagon and make it appear that he was instrumental in doing the work done by having his name on the abstract. A friend who attended the Yonkers tour has informed me that cancer cell studies and metastasis studies done in the Yonkers labs were mentioned in the slide presentation. He had made a special note of this. Maybe Ed can verify this. I am pretty sure it is those results being presented.
By: gatorbak
27 Jan 2004, 06:29 PM EST
Msg. 136650 of 136677
Jump to msg. #  

January 2004


The first shareholder tour of Advanced Viral Research Corp.'s Yonkers, NY facilities was held on January 21, 2004. Attendees were provided a slide-show on the company's research, manufacturing, intellectual property portfolio and regulatory issues. This was followed by a walk-through tour of the laboratories and manufacturing areas. Mr. Eli Wilner, CEO, and the company staff then answered a number of questions and received shareholder comments in what proved to be a very fruitful two-way session.


An interview with Eli Wilner, Chairman and interim CEO of Advanced Viral Research Corp. and Dr. James D'Olimpio, the company's «Spokesperson-at-Large» was published by Leaders magazine in their January/February 2004 issue. The interview featured a detailed discussion with Dr. D'Olimpio on the company's product, AVR 118 and its role in treating AIDS-related cachexia. Mr. Wilner addressed the manufacture and approval process for the drug, the patent protection on AVR118, its stability and the potential investment opportunity. Leaders magazine is circulated among top company executives such as CEOs, CFOs, CIOs and the investment community.


The company's drug candidate AVR118 was featured in a news segment broadcast on Channel 8 in Austin, Texas on January 7. The news clip dealt with the problem of the wasting syndrome or cachexia seen in AIDS patients and featured a short interview with Dr. D'Olimpio. While other drugs such as human drug hormone have proved effective in mitigating the body wasting, they are expensive and have undesirable side-effects. The report pointed out that the company's investigational drug AVR118, on the other hand, has not shown toxic side-effects in patients in clinical trials and is relatively inexpensive to manufacture. Channel 8 is a news channel affiliate of the local cable network in Austin.


Advanced Viral Research Corp. has been awarded a United States Patent, No. 6,670,118 entitled «Method for Treating Papillomavirus Infections». The patent describes the use of AVR118 for the topical treatment of patient suffering with lesions resulting from human papillomavirus (HPV) infections, including genital warts.

ADVR has completed a Phase I clinical trial in the U.S. to evaluate the safety of the topical application of AVR118 in healthy volunteers. There were no local adverse reactions to the application of AVR118 to the skin in these subjects. The company is now planning Phase II trials for the topical use of AVR118.


Dr. James D'Olimpio, Spokesman-at-large for ADVR is to present a paper entitled «Use of a Peptide Nucleic Acid in Cancer Regulation and Metastasis: A Preliminary Report of Bimodal Effects in Vitro». The paper is to be presented at the 1st ISC Conference on Cancer Chemotherapeutics-Molecular Targets, Pharmacology and Clinical Applications, which will take place in Florence, Italy from February 19-21, 2004. The conference is meant to provide a forum for the dissemination of the latest knowledge in the field of anticancer drug research and development, and is jointly sponsored by the International Society of Chemotherapy and the Societ Italiana di Chemioterapia. Dr. DOlimpio will be presenting the results of scientific research spearheaded and conducted by the companys scientists, Dr. Maribel deDiego and Dr. Sharon Malia on the effects of AVR118 against tumor cell lines in vitro.

Eli Wilner
Chairman and Interim CEO

Note: The information contained herein contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to complete the clinical trials of AVR118. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Past Progress Reports
Back to Corporate Update

By: SUE32073
27 Jan 2004, 07:56 PM EST
Msg. 136667 of 136677
Jump to msg. #  
"Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) today announced that its spokesperson James T. D'Olimpio M.D has been invited to attend and present at the 1st ISC International Conference on Cancer Therapeutics Molecular Targets, Pharmacology and Clinical Applications to be held in Florence, Italy, from February 19 - 21, 2004."

Note: Dr. Jim HAS BEEN INVITED TO PRESENT.....Does this mean ADVR doesn't have to pay for expenses involved in order for him to attend? Just curious!!

By: lunker10706
27 Jan 2004, 07:57 PM EST
Msg. 136668 of 136677
(This msg. is a reply to 136666 by tellslikeitis.)
Jump to msg. #  
Tells it: Who better than....

a triple board certified doctor who is actually in the "cancer bizz" to present information on a drug that shows promise in the cancer bizz. He IS the spokesperson for the company and regardless who did the research, he IS the spokesperson for ADVR and AVR118. I'd rather him speak than Dr. Kavorkian!

He seems to be a genuine, honest learned man who doesn't make a cent sitting on the board. At least he doesn't draw a salary. (Maybe he has shares?)

I think it's wonderful he's representing ADVR.
And Andy at ADVR said he was a real fine man.